Emerging Infectious Diseases (Aug 2015)

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies

  • Suzanne Tavitian,
  • Jean-Marie Peron,
  • Françoise Huguet,
  • Nassim Kamar,
  • Florence Abravanel,
  • Odile Beyne-Rauzy,
  • Lucie Oberic,
  • Stanislas Faguer,
  • Laurent Alric,
  • Murielle Roussel,
  • Clément Gaudin,
  • Loïc Ysebaert,
  • Anne Huynh,
  • Christian Recher

DOI
https://doi.org/10.3201/eid2108.150199
Journal volume & issue
Vol. 21, no. 8
pp. 1466 – 1469

Abstract

Read online

Findings among a cohort of 26 patients who had hematologic malignancies and hepatitis E virus (HEV) infection support that HEV can induce chronic hepatitis. However, a 3-month course of ribavirin can induce a rapid viral clearance, reducing the risk for chronic hepatitis and enabling continuation of cytotoxic treatments for underlying malignancies.

Keywords